Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma
Jahan S. Khalili, Shujuan Liu, Tania Rodríguez-Cruz, et al.
Clinical Cancer Research (2012) Vol. 18, Iss. 19, pp. 5329-5340
Open Access | Times Cited: 288

Showing 1-25 of 288 citing articles:

Understanding the tumor immune microenvironment (TIME) for effective therapy
Mikhail Binnewies, Edward W. Roberts, Kelly Kersten, et al.
Nature Medicine (2018) Vol. 24, Iss. 5, pp. 541-550
Open Access | Times Cited: 4450
Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives
Xiaoqi Mao, Jin Xu, Wei Wang, et al.
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 1403
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Weiyi Peng, Jie Qing Chen, Chengwen Liu, et al.
Cancer Discovery (2015) Vol. 6, Iss. 2, pp. 202-216
Open Access | Times Cited: 1345
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
Sherene Loi, Stefan Michiels, Roberto Salgado, et al.
Annals of Oncology (2014) Vol. 25, Iss. 8, pp. 1544-1550
Open Access | Times Cited: 1170
T Cell Dysfunction in Cancer
Daniela S. Thommen, Ton N. Schumacher
Cancer Cell (2018) Vol. 33, Iss. 4, pp. 547-562
Open Access | Times Cited: 1007
Combination cancer immunotherapies tailored to the tumour microenvironment
Mark J. Smyth, Shin Foong Ngiow, Antoni Ribas, et al.
Nature Reviews Clinical Oncology (2015) Vol. 13, Iss. 3, pp. 143-158
Closed Access | Times Cited: 845
Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy
Tongyan Liu, Chencheng Han, Siwei Wang, et al.
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 706
PD-L1 expression in human cancers and its association with clinical outcomes
Jinming Yu, Xin Wang, Feifei Teng, et al.
OncoTargets and Therapy (2016) Vol. Volume 9, pp. 5023-5039
Open Access | Times Cited: 691
Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
Daniel S. Chen, Bryan Irving, F. Stephen Hodi
Clinical Cancer Research (2012) Vol. 18, Iss. 24, pp. 6580-6587
Closed Access | Times Cited: 605
The Dark Side of Fibroblasts: Cancer-Associated Fibroblasts as Mediators of Immunosuppression in the Tumor Microenvironment
Lea Monteran, Neta Erez
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 554
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy
Tina Cascone, Jodi A. McKenzie, Rina M. Mbofung, et al.
Cell Metabolism (2018) Vol. 27, Iss. 5, pp. 977-987.e4
Open Access | Times Cited: 504
Regulatory circuits of T cell function in cancer
Daniel E. Speiser, Ping‐Chih Ho, Grégory Verdeil
Nature reviews. Immunology (2016) Vol. 16, Iss. 10, pp. 599-611
Closed Access | Times Cited: 499
The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
Xiaofeng Jiang, Jun Zhou, Anita Giobbie‐Hurder, et al.
Clinical Cancer Research (2012) Vol. 19, Iss. 3, pp. 598-609
Open Access | Times Cited: 441
Big opportunities for small molecules in immuno-oncology
Jerry L. Adams, James Smothers, Roopa Srinivasan, et al.
Nature Reviews Drug Discovery (2015) Vol. 14, Iss. 9, pp. 603-622
Closed Access | Times Cited: 432
The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
Li Liu, Patrick A. Mayes, Stephen D. Eastman, et al.
Clinical Cancer Research (2015) Vol. 21, Iss. 7, pp. 1639-1651
Open Access | Times Cited: 410
Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts
Linda Ziani, Salem Chouaı̈b, Jérôme Thiery
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 322
Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment
Monica Marzagalli, Nancy D. Ebelt, Edwin R. Manuel
Seminars in Cancer Biology (2019) Vol. 59, pp. 236-250
Open Access | Times Cited: 274
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Deborah A. Knight, Shin Foong Ngiow, Ming Li, et al.
Journal of Clinical Investigation (2013) Vol. 123, Iss. 3, pp. 1371-1381
Open Access | Times Cited: 266
Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
Zachary A. Cooper, Vikram R. Juneja, Peter T. Sage, et al.
Cancer Immunology Research (2014) Vol. 2, Iss. 7, pp. 643-654
Open Access | Times Cited: 242
Checkpoint blocking antibodies in cancer immunotherapy
Chrisann Kyi, Michael A. Postow
FEBS Letters (2013) Vol. 588, Iss. 2, pp. 368-376
Open Access | Times Cited: 240
Interleukin-1β and Cancer
Cédric Rébé, François Ghiringhelli
Cancers (2020) Vol. 12, Iss. 7, pp. 1791-1791
Open Access | Times Cited: 229
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
Ryan J. Sullivan, Omid Hamid, René González, et al.
Nature Medicine (2019) Vol. 25, Iss. 6, pp. 929-935
Closed Access | Times Cited: 219
Pathways and therapeutic targets in melanoma
Emma Shtivelman, Michael A. Davies, Patrick Hwu, et al.
Oncotarget (2014) Vol. 5, Iss. 7, pp. 1701-1752
Open Access | Times Cited: 205
Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies
Rana Mhaidly, Fatima Mechta‐Grigoriou
Seminars in Immunology (2020) Vol. 48, pp. 101417-101417
Open Access | Times Cited: 205
The MYC oncogene is a global regulator of the immune response
Stephanie C. Casey, Virginie Baylot, Dean W. Felsher
Blood (2018) Vol. 131, Iss. 18, pp. 2007-2015
Open Access | Times Cited: 204
Page 1 - Next Page

Scroll to top